|
| |
Achillion PharmaceuticalsAchillion is a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative small molecule drugs that combat drug resistance in infectious diseases, with a particular emphasis on antiviral drugs to treat diseases caused by hepatitis B and C viruses (HBV and HCV), HIV and herpes viruses.
Product Candidate Portfolio
The Company’s broad drug development pipeline includes antiviral compounds licensed from Yale University as well as those developed using our proprietary Zinc Finger Targeting (ZFT) technology. Achillion focuses on developing drugs to treat diseases caused by:
• Human immunodeficiency virus (HIV)
• Hepatitis B virus (HBV)
• Hepatitis C virus (HCV) • Herpes viruses
• Bacteria
• Fungi
| Contact Details: |
| 300 George Street |
| New Haven |
| |
| 06511 |
| United States of America |
| Tel: | (203) 624 7000 |
| Fax: | (203) 624 7003 |
| Email: | keastwood@achillion.com |
| WWW: | www.achillion.com/
|
| |
Recent Publications by Achillion Pharmaceuticals: |  |
Studying HCV RNA synthesis in vitro with replication complexes.
HCV replication complexes are well-organized protein and lipid structures... | 7th March, 2009
| Achillion Pharmaceuticals, New Haven, CT, USA.
| Methods Mol Biol. 2009;510:177-84.
DOI Direct Link |
Recent advances in bacterial topoisomerase inhibitors.
Bacterial topoisomerase inhibitors continue to be actively developed as... | 31st January, 2009
| Achillion Pharmaceuticals, Inc., 300 George Street, New Haven, CT 06511,
| Curr Opin Pharmacol. 2008 Oct;8(5):574-81. Epub 2008 Jun 12.
DOI Direct Link |
Internal cleavages of hepatitis C virus NS3 induced by P1 mutations at the NS3/4A cleavage site.
Despite being the focus of intensive investigation for its enzymatic... | 30th January, 2009
| Antiviral Drug Discovery, Achillion Pharmaceuticals, Inc., New Haven, CT
| Virology. 2009 Jan 20;383(2):271-8. Epub 2008 Nov 25.
DOI Direct Link |
A highly sensitive and reproducible HCV RNA hybridization method valuable for antiviral drug discovery.
Real-time RT-PCR and Northern blot are employed for the measurement of HCV... | 20th September, 2008
| Achillion Pharmaceuticals, 300 George Street, New Haven, CT 06511, USA.
| J Virol Methods. 2008 Jul;151(1):154-7. Epub 2008 May 8.
DOI Direct Link |
Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
We have discovered a novel class of compounds active against hepatitis C... | 17th July, 2008
| Achillion Pharmaceuticals, New Haven, CT 06511, USA.
| Antimicrob Agents Chemother. 2008 Jun;52(6):2043-52. Epub 2008 Apr 14.
DOI Direct Link |
→View more Achillion Pharmaceuticals research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 648 times since April 2007, the link to the organisation's website has been followed 97 times Search for more companies in New Haven Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Achillion Pharmaceuticals |
